We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




Glycemic Markers Influenced by Chronic Kidney Disease

By LabMedica International staff writers
Posted on 18 Feb 2020
Print article
Image: The ABX Pentra 400 is a compact clinical chemistry benchtop autoanalyzer (Photo courtesy of Horiba Medical).
Image: The ABX Pentra 400 is a compact clinical chemistry benchtop autoanalyzer (Photo courtesy of Horiba Medical).
Chronic kidney disease (CKD) is estimated to affect about 10% of the general adult population and is even more prevalent in diabetic patients. It is estimated that 20%–40% of individuals with diabetes have moderate to severe CKD, ranking diabetes as the leading cause of end-stage renal disease (ESRD) and an important risk factor for morbidity and mortality in dialysis patients.

It is known that good glycemic control predicts better clinical outcomes for patients with diabetes, by limiting morbidity and mortality associated with cardiovascular complications and end-organ damage. It has been suggested that the relationship between glycated hemoglobin A1c (HbA1c) and blood glucose concentration is altered as the glomerular filtration rate (GFR) declines.

Scientists at the South African Medical Research Council (Cape Town, South Africa) and their colleagues assess whether the agreement between fasting glucose and glycated proteins is affected by chronic kidney disease (CKD) in a community-based sample of 1,621 mixed-ancestry South Africans. A standard oral glucose tolerance test (OGTT) was performed by drawing a blood sample after an overnight fast, as well as two hours after a 75 g oral glucose load, to determine plasma glucose and serum insulin concentrations.

Plasma glucose levels were measured by enzymatic hexokinase method (Beckman AU, Beckman Coulter, Midrand, South Africa) and serum insulin with a paramagnetic particle chemiluminescence assay (Beckman DXI). HbA1c was analyzed with high-performance liquid chromatography (Bio-Rad Variant Turbo, Bio-Rad, Cape Town, South Africa), whereas hemoglobin was measured on a Coulter LH 750 hematology analyzer and fructosamine was determined by immunoturbidimetry on an ABX Pentra 400 autoanalyzer (Horiba Medical, Irvine, CA, USA).

The investigators reported that of those 96 with CKD, 79%, 16% and 5% where in stages 3, 4 and 5, respectively. Those with CKD had higher levels of HbA1c (6.2% versus 5.7%), glycated albumin (15.0% versus 13.0%) and fructosamine levels (269.7 versus 236.4 μmol/L), compared to those without CKD. Higher fasting glucose levels were associated with higher HbA1c, glycated albumin and fructosamine, independent of age, gender, and CKD. However, the association with HbA1c and glycated albumin differed by CKD status, at the upper concentrations of the respective markers.

The authors concluded that though HbA1c and glycated albumin perform acceptably under conditions of normoglycemia, but their findings suggest that these markers significantly underestimate true glycemic levels in people with CKD, not on dialysis. The results suggest that fructosamine may potentially be a more reliable marker of glycemic levels in those with CKD with elevated fasting blood glucose. The study was published on January 30, 2020 in the journal BMC Nephrology.

Related Links:
South African Medical Research Council
Beckman Coulter
Bio-Rad
Horiba Medical


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.